Pharma BD Deal Intelligence
Nebula Genomics founded by Harvard geneticist George Church acquired by ProPhase Labs in 2021 for consumer whole genome sequencing services
ProPhase Labs acquires Nebula Genomics whole genome sequencing company to integrate with CLIA-certified molecular testing laboratories
ProPhase Labs acquires whole genome sequencing company Nebula Genomics for approximately $14.6 million in stock and cash combination
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
ProPhase Labs (Nasdaq: PRPH) acquired whole-genome-sequencing direct-to-consumer company Nebula Genomics, announced and closed August 11, 2021, for consideration of $7.3M cash plus $7.3M in ProPhase stock (Nebula became a wholly owned subsidiary). The acquisition added consumer whole-genome sequencing (later marketed as DNA Complete) to ProPhase's diagnostics/genomics push alongside its COVID-19 testing business. Post-close (FY2025), ProPhase restructured the asset: it shut its genomics laboratory in February 2025, ran a strategic-alternatives/sale process for Nebula, and deconsolidated the business -- recognizing a $43.491M 'Investment in unconsolidated affiliates' on the December 31, 2025 balance sheet (deconsolidation of ~$16.0M of subsidiary assets and liabilities). Management reported Nebula/DNA Complete operating profitably on a standalone basis at year-end 2025.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| ProPhase Labs / Nebula Genomics (this deal) | 2021 | $15M | 48 |
| Merck & Co. Inc. / Acceleron Pharma Inc. | 2021 | $11.5B | 90 |
| Amgen Inc. / Five Prime Therapeutics | 2021 | $1.9B | 78 |
| Thermo Fisher Scientific Inc. / PPD Inc. | 2021 | $17.4B | 77 |
| Pfizer Inc. / Arvinas, Inc. | 2021 | $2.4B | 77 |
| Jazz Pharmaceuticals PLC / GW Pharmaceuticals | 2021 | $7.2B | 77 |
| Sanofi SA / Amunix Pharmaceuticals Inc. | 2021 | $1.2B | 76 |
← Browse all deals · How we score deals
More: 2021 deals